Belief BioMed Successfully Completed Dosing of First Subject in the Registrational Clinical Trial for Hemophilia A
- Written by PR Newswire
SHANGHAI, Jan. 3, 2024 /PRNewswire/ -- Belief BioMed Group (BBM), an industry-leading biotech company focusing on innovative gene therapies, announced the completion of first subject dosing in its registrational clinical trial (CTR20233400) of BBM-H803, a gene therapy for hemophilia A, independently developed and produced by Belief BioMed.
BBM-H803...
